GILEAD SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.05 USD | -0.63% |
|
-0.56% | -19.58% |
| May. 07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
| May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 81.63B | ||||||
| 700B | ||||||
| 358B | ||||||
| 330B | ||||||
| 287B | ||||||
| 236B |
